Wedbush Issues Positive Forecast for SWTX Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Wedbush boosted their Q2 2025 earnings estimates for shares of SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.68) for the quarter, up from their previous forecast of ($0.71). Wedbush currently has a "Outperform" rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics' current full-year earnings is ($3.04) per share. Wedbush also issued estimates for SpringWorks Therapeutics' Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

Several other research analysts have also recently weighed in on SWTX. Guggenheim decreased their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Finally, Evercore ISI raised their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of "Buy" and an average price target of $70.83.

SpringWorks Therapeutics Price Performance

SWTX stock traded down $0.57 on Monday, reaching $55.73. 2,537,541 shares of the company traded hands, compared to its average volume of 2,646,772. The company has a market cap of $4.15 billion, a P/E ratio of -14.36 and a beta of 0.81. The firm has a fifty day simple moving average of $40.27 and a 200-day simple moving average of $37.31. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $60.00.

Institutional Trading of SpringWorks Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Huntington National Bank increased its holdings in shares of SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after acquiring an additional 192 shares during the period. AlphaQuest LLC boosted its position in SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in SpringWorks Therapeutics in the fourth quarter valued at about $45,000. State of Wyoming raised its holdings in SpringWorks Therapeutics by 39.5% in the fourth quarter. State of Wyoming now owns 1,530 shares of the company's stock worth $55,000 after purchasing an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in SpringWorks Therapeutics in the fourth quarter worth about $56,000.

Insider Activity at SpringWorks Therapeutics

In related news, CEO Saqib Islam sold 48,000 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,002,502 shares of the company's stock, valued at $53,433,356.60. This represents a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the completion of the sale, the chief operating officer now directly owns 209,600 shares of the company's stock, valued at $8,796,912. The trade was a 8.71 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 313,822 shares of company stock worth $16,802,876. Insiders own 7.61% of the company's stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.